ALLO Revenue Flow Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.
2017-12-31: Research and development $0.00 ; Operating expenses $2.00K ; Income tax $0.00 ; Net income -$2.00K . Schedule Of Equity Method Investment Equity Method Investee Name Separate filed amounts; connecting flows are not established. Components and totals may overlap.
ALLO revenue flow Filed amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow. Overland Therapeutics Formerly Known As Allogene Overland $4.60M Revenue $4.64M Operating expenses $51.56M Operating income -$46.92M Other income, net -$61.00K Research & development $30.72M Net income -$42.68M
Segment Separate filed amounts; connecting flows are not established. Components and totals may overlap.
ALLO revenue flow Filed amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow. Reportable Segment $4.64M Revenue $4.64M Operating expenses $51.56M Operating income -$46.92M Other income, net -$61.00K Research & development $30.72M Net income -$42.68M
Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.
Historical revenue and expense breakdown Revenue and expense 1 month Period end Research and development Operating expenses Income tax Net income 2017-12-31 $0.00 $2.00K $0.00 -$2.00K
Revenue and expense 3 month Period end Revenue Research and development Operating expenses Income tax Net income 2026-06-30 $4.64M $30.72M $51.56M (m) -$42.68M 2026-03-31 (m) $32.00M $46.09M (m) -$42.61M 2025-12-31 $0.00* $28.63M* $42.40M* (m) -$38.81M* 2025-09-30 $0.00 $31.16M $44.90M (m) -$41.40M 2025-06-30 $0.00 $40.16M $56.82M (m) -$50.94M 2025-03-31 $0.00 $50.20M $65.19M (m) -$59.73M 2024-09-30 $0.00 $44.71M $71.77M (m) -$66.29M 2024-06-30 $0.00 $50.35M $71.43M (m) -$66.36M 2024-03-31 $22.00K $52.26M $69.53M (m) -$65.00M 2023-09-30 $22.00K $45.98M $63.02M (m) -$62.29M 2023-06-30 $22.00K $62.04M $80.56M (m) -$79.23M 2023-03-31 $30.00K $80.24M $99.12M (m) -$99.97M 2022-09-30 $27.00K $63.64M $82.54M (m) -$84.24M 2022-06-30 $64.00K $57.17M $76.68M (m) -$80.29M 2022-03-31 $39.00K $60.16M $80.05M (m) -$78.61M 2021-09-30 $49.00K $58.72M $77.72M (m) -$78.19M 2021-06-30 $44.00K $52.29M $71.07M (m) -$70.94M 2021-03-31 $38.34M $55.18M $71.55M (m) -$33.02M 2020-09-30 $0.00 $51.42M $68.04M $0.00 -$66.20M 2020-06-30 $0.00 $47.30M $63.16M $0.00 -$60.97M 2020-03-31 $0.00 $42.04M $57.68M $0.00 -$54.48M 2019-12-31 (m) (m) (m) (m) -$61.03M 2019-09-30 (m) $39.99M $55.01M $33.00K -$50.73M 2019-06-30 (m) $31.77M $45.96M -$159.00K -$41.24M 2019-03-31 (m) $23.40M $36.46M -$50.00K -$31.59M 2018-12-31 (m) (m) (m) (m) -$30.51M 2018-09-30 (m) $10.87M $22.19M $0.00 -$43.50M 2018-06-30 (m) $122.49M $135.01M $0.00 -$134.90M 2018-03-31 (m) (m) $2.60M (m) -$2.60M
Revenue and expense 6 month Period end Revenue Research and development Operating expenses Income tax Net income 2026-06-30 $4.64M $62.72M $97.65M (m) -$85.28M 2025-06-30 $0.00 $90.36M $122.01M (m) -$110.68M 2024-06-30 $22.00K $102.61M $140.96M (m) -$131.36M 2023-06-30 $52.00K $142.28M $179.68M (m) -$179.20M 2022-06-30 $103.00K $117.33M $156.73M (m) -$158.90M 2021-06-30 $38.39M $107.47M $142.62M (m) -$103.95M 2020-06-30 $0.00 $89.34M $120.84M $0.00 -$115.45M 2019-06-30 (m) $55.18M $82.42M -$209.00K -$72.83M 2018-06-30 (m) $122.49M $137.61M $0.00 -$137.50M
Revenue and expense 9 month Period end Revenue Research and development Operating expenses Income tax Net income 2025-09-30 $0.00 $121.52M $166.91M (m) -$152.08M 2024-09-30 $22.00K $147.33M $212.73M (m) -$197.65M 2023-09-30 $74.00K $188.25M $242.70M (m) -$241.49M 2022-09-30 $130.00K $180.97M $239.27M (m) -$243.14M 2021-09-30 $38.44M $166.19M $220.34M (m) -$182.14M 2020-09-30 $0.00 $140.76M $188.88M $0.00 -$181.65M 2019-09-30 (m) $95.17M $137.43M -$176.00K -$123.56M 2018-09-30 (m) $133.36M $159.80M $0.00 -$181.00M
Revenue and expense 12 month Period end Revenue Research and development Operating expenses Income tax Net income 2025-12-31 $0.00 $150.15M $209.31M $0.00 -$190.89M 2024-12-31 $22.00K $192.30M $273.22M $443.00K -$257.59M 2023-12-31 $95.00K $242.91M $327.83M $0.00 -$327.26M 2022-12-31 $156.00K $256.39M $335.69M $0.00 -$340.41M 2021-12-31 $114.09M $220.18M $294.28M $0.00 -$182.05M 2020-12-31 $0.00 $192.99M $258.24M $0.00 -$316.38M 2019-12-31 $0.00 $144.53M $202.01M -$331.00K -$184.59M 2018-12-31 (m) $151.86M $192.84M -$117.00K -$211.50M